Marker Therapeutics Inc
NASDAQ:MRKR

Watchlist Manager
Marker Therapeutics Inc Logo
Marker Therapeutics Inc
NASDAQ:MRKR
Watchlist
Price: 2.86 USD Market Closed
Market Cap: 30.6m USD

Marker Therapeutics Inc
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Marker Therapeutics Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Marker Therapeutics Inc
NASDAQ:MRKR
Common Stock
$8.9k
CAGR 3-Years
-52%
CAGR 5-Years
-29%
CAGR 10-Years
-33%
Abbvie Inc
NYSE:ABBV
Common Stock
$18m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Common Stock
$33.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Common Stock
$2.6m
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
3%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Common Stock
$101.8k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Marker Therapeutics Inc
Glance View

Market Cap
30.6m USD
Industry
Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

MRKR Intrinsic Value
3.8 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Marker Therapeutics Inc's Common Stock?
Common Stock
8.9k USD

Based on the financial report for Sep 30, 2024, Marker Therapeutics Inc's Common Stock amounts to 8.9k USD.

What is Marker Therapeutics Inc's Common Stock growth rate?
Common Stock CAGR 10Y
-33%

Over the last year, the Common Stock growth was -11%. The average annual Common Stock growth rates for Marker Therapeutics Inc have been -52% over the past three years , -29% over the past five years , and -33% over the past ten years .

Back to Top